PDL BioPharma — Q4 2018 Earnings Presentation
12 slides from PDL BioPharma's earnings presentation, Mar 14, 2019
Slide 1: 2018 Fourth Quarter and Full Year Financial Results Conference Call
PDL 2018 Fourth Quarter and Full Year Financial Results Conference Calll March 14, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual
Slide 3: Financial Highlights: 4Q and FY 2018
Financial Highlights: 4? Quarter and FY 2018 o Fourth Quarter 2018: = Revenues - $45 million — Productrevenues - $26 million + Noden product sales - $19 million + LENSAR product revenues - $7 million = Consolidated GAAP net income - $16 million, or $0.11 per diluted share. o Full Year 2018: = Revenu
Slide 4: Strategy For Shareholder Value Creation
Strategy For Shareholder Value Creation What we are looking for: + Commercial-stage products and/or companies with multi-year sales growth potential and which performance may be improved through access to PDL’s capital and expertise. + Late development stage assets or pre-commercialization products.
Slide 5: What Do We Have To Offer?
What Do We Have To Offer? o Fulfill the full product potential or technology promise: = Through adequate and secured funding = Build on the existing team or establish a specifically tailored organization dedicated to the success of the asset = Opportunity for continued involvement, leveraging PDL ex
Slide 6: Noden: Focus on Profitability
Noden: Focus on Profitability o Actions to increase the profitability of Tekturna® and mitigate the impact of potential Tekturna® NRx generic competition include: eon ae aw 120 - Discontinued contract sales force in a Yn 4} August 2018 resulting in savings of = PpeateerN SN JP $3.5 to $4 million per
Slide 7: LENSAR: Continued Innovation
LENSAR: Continued Innovation o LENSAR reported revenues of $7.2 million in Q4 2018. = 8 percent increase over Q3 2018. o Q4 2018 GAAP net loss of approx. $1.7 million. = Break-even on an EBITDA basis. o Utilized NOLs resulting in cash savings of $2.8 million in 2018. o Substantial growth opportuniti
Slide 8: Share Repurchase Programs
Share Repurchase Programs o While our focus is on the strategic acquisition of biopharma assets, given the significant discount of PDL’s stock price to its book value, we have implemented share repurchase programs to return value to shareholders. o Completed $55 million in two initial stock repurcha
Slide 9: Book Value Increased $0.63 in Q4 as a Result of Stock Repurchase Program
Book Value Increased $0.63 in Q4 18 as a Result of Stock Repurchase Program. PDL’s book value for the period ending December 31, 2018 was $5.70 PDL's Book Value Per Share BUShausS Sashsas aS 8b SSSR EE NN NNO LORS EE TAGS SShahseas Sshsashsa SSSh5 Sashs 3 3 4 14 a 4 5 5 Jun-7 Sep7 pec? Maras Jun-18
Slide 10: Fourth Quarter 2018 Financials
Fourth Quarter 2018 Financials Three Months Ended ‘Twelve Months Ended December 31, December 31, (in thousands, except per share amounts) 2018 2017 2018 2017 Royalties from Queen et al. patents § 2 § 4531 § 4536 § 36,415 Royalty rights change in fair value 19,139 30,103 95,256 _ 162,327 Interest rev
Slide 11: Fourth Quarter 2018 Financials
11 Fourth Quarter 2018 Financials (in thousands) GAAP net income (oss) attributed to PDL's shareholders as reported Adjustments: Mark-to-market adjustment to fair value assets Non-cash interest revenues Non-Cash stock-based compensation expense Non-cash debt offering costs Mark-to-market adjustment
Slide 12: Fourth Quarter 2018 Financials
Fourth Quarter 2018 Financials Consolidated balance sheet data (unaudited) (in thousands) Cash, cash equivalents and investments Total notes receivable Royalty rights - at fair value Intangible assets, net Total assets Convertible notes payable Total stockholders’ equity December 31, September 30, D